Prostate Cancer

Addition of Radiation Improves Survival in High-Risk Prostate Cancer (05-18-2016)

The addition of radiation therapy to androgen-deprivation therapy among men with prostate cancer who are at a high risk of a cancer recurrence significantly improves long-term survival. These results were recently published in the journal of European... Continue Reading

Chemotherapy After Prostatectomy Delays Cancer Progression in High-Risk Prostate Cancers (05-17-2016)

The use of chemotherapy following a radical prostatectomy delays the time to cancer progression among men with prostate cancer who are at a high risk of developing a recurrence.  These results were recently presented at the 2016 Annual Scientific Meeting... Continue Reading

Longer Duration of Androgen Deprivation Therapy Increases Risk of Depression in Early Prostate Cancer (04-25-2016)

Among men with early prostate cancer, the risk of depression is increased with the use of androgen-deprivation therapy (ADT), particularly among men who are treated with ADT for 12 months or longer.  It is important for patients receiving ADT to speak... Continue Reading

Radiotherapy for Prostate Cancer Increases Risk of Secondary Cancers (03-14-2016)

Patients with prostate cancer considering radiation therapy should now be informed that radiotherapy raises the risk of developing a secondary cancer. Prostate cancer patients who undergo radiotherapy raise their risk of getting other cancers by nearly... Continue Reading

Shorter Radiation Schedule Effective in Low-Risk Prostate Cancer (03-9-2016)

Men with low-grade prostate cancer have the same long-term outcomes when they are treated with a shorter radiation schedule, compared to those treated with a longer, conventional radiation schedule. These results were recently presented at the 2016 annual... Continue Reading

Xtandi® Improves Survival in Advanced Prostate Cancer (02-22-2016)

The agent Xtandi® (enzalutamide) improves survival and reduces the time to cancer progression compared to Casodex® (bicalutamide) among men with prostate cancer that has stopped responding to prior therapy with antiandrogens. These results were recently... Continue Reading

Prostate Cancer: Year in Review (02-2-2016)

In 2015, the increased use of Oncotype DX prostate cancer test promoted changes in treatment received, resulting in greater recommendations and adoption of active surveillance. Also noteworthy is the research devoted to best standard of treatment for... Continue Reading

Shorter Course of Radiation as Effective as Longer Course in Low-Risk Prostate Cancer (11-5-2015)

A shorter course of hypofractionated radiation therapy, a treatment in which larger doses of radiation are delivered over a shorter time period than conventional radiation, appears as effective as longer courses for men with low-risk prostate cancer.... Continue Reading

Combined Hormone and Radiation Therapy Superior to Radiation Alone for Prostate Cancer Recurring After Prostatectomy (11-4-2015)

The addition of two years of anti-androgen therapy (AAT) to radiation therapy reduces the risk of death caused by prostate cancer among men treated for a recurrence following a prostatectomy. Treatment for early prostate cancer often includes the surgical... Continue Reading

Gene-Targeted Drug Can Treat Prostate Cancer (10-29-2015)

According to an international consortium of researchers led by experts at The Institute of Cancer Research, London, and The Royal Marsden, a pioneering drug developed to treat women with inherited cancers can also benefit men with advanced prostate cancer. Olaparib,... Continue Reading

« Previous PageNext Page »